Computational Modeling Core
Computational Modeling Core
批准号:
10353542
负责人:
Qiang Zhang
金额:
$23.18万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-04-01 至 2027-06-30
关键词:
AddressAdoptedAryl Hydrocarbon ReceptorB-LymphocytesBacteriaBinding ProteinsBioinformaticsBiologicalBiological AvailabilityBiological ModelsBiomedical EngineeringBioremediationsCYP1A2 geneCarbonCellsCobalaminCollaborationsCommunitiesComplementComplexComputer ModelsDataData SetDecision MakingDioxinsDoseEngineeringEnvironmental Engineering technologyEnvironmental PollutionEnzymesEvaluationEventExposure toFatty LiverFeedbackFoundationsFuransGenerationsGenetic TranscriptionHealthHepaticHepatocyteHepatotoxicityHomeostasisHumanImmunityImmunoglobulin MImmunosuppressionIn VitroInformaticsInvestigationLaboratory StudyLinkLipidsLiverMediatingMetabolicMichiganModelingMolecularMusNonlinear DynamicsOrganismOutcomePathway interactionsPharmacodynamicsPhysiologicalPopulationReceptor ActivationRegimenResearchResearch PersonnelResearch SupportResolutionRisk AssessmentRoleSignal Recognition ParticleSignal Transduction PathwaySoilSpleenStructureSuperfundSystemSystems AnalysisSystems TheoryTechniquesTestingThyroid HormonesTissuesToxic effectToxicant exposureToxicologyTrainingTranscription AlterationUniversitiesVitamin B 12adverse outcomearyl hydrocarbon receptor ligandbasebioinformatics toolbiological researchcomputational suitecomputational toxicologycomputerized toolsdesigndibenzo(1,4)dioxindosimetrydynamic systemenvironmental toxicologygene networkgene regulatory networkhigh dimensionalityhormone metabolismhuman modelhypothalamic-pituitary-thyroid axisimmunotoxicityimprovedin silicoin vitro Assayin vivoinnovationlaboratory experimentlarge datasetslipid metabolismmicrobialmodel developmentmouse modelnext generationnovelnovel markerpharmacodynamic modelpharmacokinetic modelpharmacokinetics and pharmacodynamicsphysiologically based pharmacokineticspollutantpopulation healthpredictive markerresponsesimulationsingle-cell RNA sequencingsuperfund sitesupport toolsthyroid disruptiontooluniversity student
中文摘要
药代动力学(PK)和药效学(PD)共同定义了毒物暴露于
可能导致不良后果的生物扰动。毒理学越来越多地涉及计算
补充实验室研究的方法,并提供更全面、更定量和更机械化的
人类健康风险评估的基础。计算建模核心(CMC)将提供一套
支持生物医学和环境工程项目的计算能力。中央军委
为高维基因组研究提供面向项目的生物信息学支持,以及(Iii)提供交叉
计算毒理学的学科培训。模型开发将与实验室迭代协调
由这些项目进行的实验。之前CMC与密歇根州立大学(MSU)的互动
超级基金项目已经表明,这种迭代方法对于假设的生成和评估是有效的。
在特定目标1(SA1)中,我们将建立2,3,7,8-四氯二苯-对二恶英(TCDD)和
超级基金现场相关的多氯二苯并-对二恶英和呋喃(二恶英/呋喃)。这些型号将包括
诱导肝脏CYP1A2作为二恶英结合蛋白和肝脏脂质蓄积以获得更准确的结果
对游离PCDD/F浓度的预测。这些模型将支持项目3中对小鼠的肝毒性研究
和项目5中活性碳处理土壤的PCDD/F生物有效性研究。人类PBPK模型也将
被开发来帮助在项目3和
在项目1和项目2中,基于体外测试的体内PCDD/F暴露水平的外推。在SA2中,我们将
人CD5+B细胞(方案1)和小鼠肝细胞(方案3)的细胞RNA测序数据,并应用于
我们还将识别AHR干扰的基因调控网络,为SA3中的途径建模提供信息。在SA3中,
项目1的动态通路建模将解决AHR激活对PD-1抑制信号的影响
CD5+B细胞的信号转导途径。项目2:诱导肝脏甲状腺激素代谢的模型
将制定多氯二苯并二恶英/氟,以支持人口健康风险评估。对于项目3,路径建模
将专注于通过AHR介导的关键肝脏转录改变来扰乱肝脏的脂代谢
酵素。这些模型将支持对非线性剂量响应的严格研究,并提供强大的
支持机械驱动风险评估的研究基础。CMC还将支持项目4以
模拟细菌脱卤化PCDD/FS中维生素B12的回收和从头合成途径。在SA4中,
毒理学:建模和信息学将每隔一年向SRP和风险评估社区提供。
英文摘要
Pharmacokinetics (PK) and pharmacodynamics (PD) together define the continuum from toxicant exposure to
biological perturbations that can cause adverse outcomes. Toxicology increasingly involves computational
approaches that complement laboratory studies and provide a more integrated, quantitative and mechanistic
basis for human health risk assessment. The Computational Modeling Core (CMC) will provide a suite of
computational capabilities to support both the Biomedical and Environmental Engineering Projects. The CMC
will: (i) develop physiologically based PK (PBPK) and PD models of dioxins and dioxin-like compounds, (ii)
provide Project-oriented bioinformatic support for high-dimensional omic studies, and (iii) provide cross-
disciplinary training in computational toxicology. Model development will be coordinated iteratively with laboratory
experiments carried out by the Projects. Prior CMC interactions with the Michigan State University (MSU)
Superfund Projects have shown that this iterative approach is efficient for hypothesis generation and evaluation.
In Specific Aim 1 (SA1) we will develop PBPK models for 2,3,7,8-tetrachlorodiben-p-dioxin (TCDD) and
Superfund site-relevant polychlorinated dibenzo-p-dioxins and furans (PCDD/Fs). The models will include
induction of hepatic CYP1A2 as a dioxin-binding protein and liver lipid accumulation for more accurate
predictions of free PCDD/F concentrations. The models will support hepatotoxicity studies in mice in Project 3
and PCDD/F bioavailability studies of activated carbon-treated soil in Project 5. Human PBPK models will also
be developed to help establish tissue dose equivalency between mice and humans for Project 3 and for
extrapolation of in vivo PCDD/F exposure levels based on in vitro assays in Projects 1 and 2. In SA2 we will
use bioinformatic tools to parse out aryl hydrocarbon receptor (AHR)-mediated cell state trajectories from single-
cell RNA sequencing data in human CD5+ B cells (Project 1) and mouse hepatocytes (Project 3), and apply
nonlinear dynamical systems analysis to identify novel biomarkers predictive of onset of AHR-mediated toxicity.
We will also identify AHR-perturbed gene regulatory networks to inform pathway modeling in SA3. In SA3,
dynamical pathway modeling for Project 1 will address the effects of AHR activation on the PD-1 inhibitory signal
transduction pathway in CD5+ B cells. For Project 2, a model of induction of hepatic thyroid hormone metabolism
by PCDD/Fs will be developed to support population health risk assessment. For Project 3, pathway modeling
will focus on disruption of hepatic lipid metabolism through AHR-mediated transcriptional alteration of key liver
enzymes. These models will support rigorous investigation of nonlinear dose-responses and provide a strong
foundation for research supporting mechanistically-driven risk assessment. CMC will also support Project 4 to
model the vitamin B12 salvaging and de novo synthesis pathways in bacteria dehalogenating PCDD/Fs. In SA4,
in collaboration with RETCC, a 3-day course on PBPK modeling and a 5-day course on Computational Systems
Toxicology: Modeling and Informatics will be offered in alternate years to SRP and risk assessment communities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glycolysis and Alzheimer’s Disease
-
批准号:10703424
-
项目类别:
-
资助金额:$15.45万
-
财政年份:2022
-
负责人:Qiang Zhang
-
依托单位:
Glycolysis and Alzheimer’s Disease
-
批准号:10516234
-
项目类别:
-
资助金额:$15.45万
-
财政年份:2022
-
负责人:Qiang Zhang
-
依托单位:
The chemical approach towards homogenous glycoprotein preparation and evaluation
-
批准号:10413931
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2020
-
负责人:Qiang Zhang
-
依托单位:
The chemical approach towards homogenous glycoprotein preparation and evaluation
-
批准号:10028705
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2020
-
负责人:Qiang Zhang
-
依托单位:
The chemical approach towards homogenous glycoprotein preparation and evaluation
-
批准号:10654736
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2020
-
负责人:Qiang Zhang
-
依托单位:
The chemical approach towards homogenous glycoprotein preparation and evaluation
-
批准号:10201680
-
项目类别:
-
资助金额:$36.56万
-
财政年份:2020
-
负责人:Qiang Zhang
-
依托单位:
海外基金